[Liraglutide in obese and overweight patients]

Salvi R, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001525
Spanish
Original Title: Liraglutida en pacientes obesos y con sobrepeso
Authors' recomendations: CONCLUSIONS High-quality evidence shows that the use of subcutaneous liraglutide in obese patients or those with a body mass index greater than or equal to 27 kg/m2 with cardiovascular risk factors is associated with a greater reduction in weight percentage and decrease in body mass index than placebo at one year of treatment. The most common adverse events were gastrointestinal, associated with high treatment dropout rates due to nausea or vomiting. Low-quality evidence suggests that liraglutide versus placebo in the subgroup of patients with prediabetes associated with obesity or overweight with hypertension and/or dyslipidemia would reduce the time to develop diabetes at three years of treatment. There is consensus among the different clinical practice guidelines identified on the fact that the pharmacological treatment should be administered as complementary therapy in obese or overweight patients with risk factors who do not respond to lifestyle changes. Choosing orlistat or liraglutide should be based on their clinical effectiveness, the patient’s comorbidities and values, preferred route of administration, safety and costs. Some health sponsors from the United States provide coverage for this technology. Even though no cost-effectiveness studies carried out in Argentina have been found in obese or overweight patients, with cardiovascular risk factors, liraglutide may not be cost-effective, since its retail price is high in relation to the comparator and the relation between the cost of the intervention and the size of the net benefit is unfavorable. In the subgroup of patients with prediabetes associated with obesity or overweight with hypertension and/or dyslipidemia and other comorbidities, liraglutide compared to placebo has a greater clinical benefit so its cost-effectiveness is uncertain.
Details
Project Status: Completed
Year Published: 2019
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Obesity
  • Anti-Obesity Agents
  • Liraglutide
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.